CARIBOU BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.79 USD | -7.25% |
|
-8.21% | -68.76% |
| Jun. 04 | US Equities Markets Close Mixed Monday as US Manufacturing Contracts | MT |
| Jun. 04 | HC Wainwright Adjusts Price Target on Caribou Biosciences to $9 From $24, Maintains Buy Rating | MT |
Financials (USD)
| Sales 2024 * | 11.74M | Sales 2025 * | 12.57M | Capitalization | 162M |
|---|---|---|---|---|---|
| Net income 2024 * | -167M | Net income 2025 * | -218M | EV / Sales 2024 * | 13.8 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 12.9 x |
| P/E ratio 2024 * |
-0.97
x | P/E ratio 2025 * |
-0.86
x | Employees | 158 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.94% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -7.25% | ||
| 1 week | -8.21% | ||
| Current month | -37.85% | ||
| 1 month | -50.82% | ||
| 3 months | -66.60% | ||
| 6 months | -70.99% | ||
| Current year | -68.76% |
1 week
1.78
2.12
1 month
1.753.72
Current year
1.758.33
1 year
1.758.59
3 years
1.7532.65
5 years
1.7532.65
10 years
1.7532.65
| Managers | Title | Age | Since |
|---|---|---|---|
Rachel Haurwitz
FOU | Founder | 37 | 11-10-27 |
Jason O’Byrne
DFI | Director of Finance/CFO | 55 | 21-02-08 |
Steven Kanner
CTO | Chief Tech/Sci/R&D Officer | 65 | 17-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 55 | 21-03-31 | |
Scott Braunstein
BRD | Director/Board Member | 60 | 21-05-31 |
| Director/Board Member | 60 | 21-11-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.97% | 2 M€ | -25.75% | ||
| 0.61% | 15 M€ | -2.91% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 1.79 | -7.25% | 3,220,151 |
| 24-06-13 | 1.93 | -2.03% | 1,572,697 |
| 24-06-12 | 1.97 | +1.55% | 2,524,909 |
| 24-06-11 | 1.94 | +3.19% | 5,255,419 |
| 24-06-10 | 1.88 | -3.59% | 3,463,068 |
Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm EDT
More quotes
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.79
USD
Average target price
16.62
USD
Spread / Average Target
+828.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -68.76% | 162M | |
| +40.80% | 53.67B | |
| +35.79% | 38.86B | |
| -8.05% | 38.76B | |
| -8.98% | 27.27B | |
| +10.69% | 25.91B | |
| -16.21% | 20.29B | |
| +31.00% | 12.78B | |
| +28.51% | 12.18B | |
| -1.67% | 11.96B |
- Stock Market
- Equities
- CRBU Stock
